Marchés français ouverture 39 min
  • Dow Jones

    30 932,37
    -469,63 (-1,50 %)
     
  • Nasdaq

    13 192,35
    +72,95 (+0,56 %)
     
  • Nikkei 225

    29 663,50
    +697,49 (+2,41 %)
     
  • EUR/USD

    1,2095
    +0,0007 (+0,06 %)
     
  • HANG SENG

    29 416,60
    +436,39 (+1,51 %)
     
  • BTC-EUR

    38 217,68
    +1 236,46 (+3,34 %)
     
  • CMC Crypto 200

    922,07
    -11,06 (-1,19 %)
     
  • S&P 500

    3 811,15
    -18,19 (-0,48 %)
     

Global Meningococcal Vaccines Industry

ReportLinker
·13 min de lecture

Global Meningococcal Vaccines Market to Reach US$7. 2 Billion by the Year 2027. Amid the COVID-19 crisis, the global market for Meningococcal Vaccines estimated at US$3. 4 Billion in the year 2020, is projected to reach a revised size of US$7.

New York, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Meningococcal Vaccines Industry" - https://www.reportlinker.com/p05957343/?utm_source=GNW
2 Billion by 2027, growing at a CAGR of 11.3% over the analysis period 2020-2027.Polysaccharide Meningococcal Vaccines, one of the segments analyzed in the report, is projected to grow at a 12.4% CAGR to reach US$2.7 Billion by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Conjugate Meningococcal Vaccines segment is readjusted to a revised 11.4% CAGR for the next 7-year period. This segment currently accounts for a 21% share of the global Meningococcal Vaccines market.

The U.S. Accounts for Over 29.5% of Global Market Size in 2020, While China is Forecast to Grow at a 10.8% CAGR for the Period of 2020-2027

The Meningococcal Vaccines market in the U.S. is estimated at US$1 Billion in the year 2020. The country currently accounts for a 29.51% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$1.3 Billion in the year 2027 trailing a CAGR of 10.8% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10% and 9.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR while Rest of European market (as defined in the study) will reach US$1.3 Billion by the year 2027.

Combination Meningococcal Vaccines Segment Corners a 35% Share in 2020

In the global Combination Meningococcal Vaccines segment, USA, Canada, Japan, China and Europe will drive the 10.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$954.7 Million in the year 2020 will reach a projected size of US$1.9 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$844 Million by the year 2027.We bring years of research experience to this 6th edition of our report. The 132-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

  • Baxter International, Inc.

  • Bio-Med Pvt., Ltd.

  • GlaxoSmithKline PLC

  • Pfizer, Inc.

  • Sanofi SA

  • Serum Institute of India Pvt., Ltd.




Read the full report: https://www.reportlinker.com/p05957343/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
Global Competitor Market Shares
Meningococcal Vaccines Competitor Market Share Scenario
Worldwide (in %): 2018E

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Meningococcal
Vaccines by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Billion for Years 2018 through
2027

Table 2: World Historic Review for Meningococcal Vaccines by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Billion for Years 2012 through 2017

Table 3: World 15-Year Perspective for Meningococcal Vaccines
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2018 & 2027

Table 4: World Current & Future Analysis for Polysaccharide
Meningococcal Vaccines by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 5: World Historic Review for Polysaccharide Meningococcal
Vaccines by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Billion for Years 2012 through
2017

Table 6: World 15-Year Perspective for Polysaccharide
Meningococcal Vaccines by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2012, 2018 & 2027

Table 7: World Current & Future Analysis for Conjugate
Meningococcal Vaccines by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 8: World Historic Review for Conjugate Meningococcal
Vaccines by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Billion for Years 2012 through
2017

Table 9: World 15-Year Perspective for Conjugate Meningococcal
Vaccines by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2018 & 2027

Table 10: World Current & Future Analysis for Combination
Meningococcal Vaccines by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 11: World Historic Review for Combination Meningococcal
Vaccines by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Billion for Years 2012 through
2017

Table 12: World 15-Year Perspective for Combination
Meningococcal Vaccines by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2012, 2018 & 2027

Table 13: World Current & Future Analysis for Meningococcal B
Vaccines by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Billion for Years 2018 through
2027

Table 14: World Historic Review for Meningococcal B Vaccines by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Billion for Years 2012 through 2017

Table 15: World 15-Year Perspective for Meningococcal B
Vaccines by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2018 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
Market Facts & Figures
US Meningococcal Vaccines Market Share (in %) by Company:
2018 & 2027
Market Analytics
Table 16: USA Current & Future Analysis for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines - Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 17: USA Historic Review for Meningococcal Vaccines by
Type - Polysaccharide Meningococcal Vaccines, Conjugate
Meningococcal Vaccines, Combination Meningococcal Vaccines and
Meningococcal B Vaccines Markets - Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 18: USA 15-Year Perspective for Meningococcal Vaccines by
Type - Percentage Breakdown of Value Sales for Polysaccharide
Meningococcal Vaccines, Conjugate Meningococcal Vaccines,
Combination Meningococcal Vaccines and Meningococcal B Vaccines
for the Years 2012, 2018 & 2027

CANADA
Table 19: Canada Current & Future Analysis for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines - Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 20: Canada Historic Review for Meningococcal Vaccines by
Type - Polysaccharide Meningococcal Vaccines, Conjugate
Meningococcal Vaccines, Combination Meningococcal Vaccines and
Meningococcal B Vaccines Markets - Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 21: Canada 15-Year Perspective for Meningococcal Vaccines
by Type - Percentage Breakdown of Value Sales for
Polysaccharide Meningococcal Vaccines, Conjugate Meningococcal
Vaccines, Combination Meningococcal Vaccines and Meningococcal
B Vaccines for the Years 2012, 2018 & 2027

JAPAN
Table 22: Japan Current & Future Analysis for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines - Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 23: Japan Historic Review for Meningococcal Vaccines by
Type - Polysaccharide Meningococcal Vaccines, Conjugate
Meningococcal Vaccines, Combination Meningococcal Vaccines and
Meningococcal B Vaccines Markets - Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 24: Japan 15-Year Perspective for Meningococcal Vaccines
by Type - Percentage Breakdown of Value Sales for
Polysaccharide Meningococcal Vaccines, Conjugate Meningococcal
Vaccines, Combination Meningococcal Vaccines and Meningococcal
B Vaccines for the Years 2012, 2018 & 2027

CHINA
Table 25: China Current & Future Analysis for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines - Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 26: China Historic Review for Meningococcal Vaccines by
Type - Polysaccharide Meningococcal Vaccines, Conjugate
Meningococcal Vaccines, Combination Meningococcal Vaccines and
Meningococcal B Vaccines Markets - Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 27: China 15-Year Perspective for Meningococcal Vaccines
by Type - Percentage Breakdown of Value Sales for
Polysaccharide Meningococcal Vaccines, Conjugate Meningococcal
Vaccines, Combination Meningococcal Vaccines and Meningococcal
B Vaccines for the Years 2012, 2018 & 2027

EUROPE
Market Facts & Figures
European Meningococcal Vaccines Market: Competitor Market Share
Scenario (in %) for 2018 & 2027
Market Analytics
Table 28: Europe Current & Future Analysis for Meningococcal
Vaccines by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ Billion for Years 2018 through 2027

Table 29: Europe Historic Review for Meningococcal Vaccines by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Billion for Years 2012 through 2017

Table 30: Europe 15-Year Perspective for Meningococcal Vaccines
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2018 & 2027

Table 31: Europe Current & Future Analysis for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines - Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 32: Europe Historic Review for Meningococcal Vaccines by
Type - Polysaccharide Meningococcal Vaccines, Conjugate
Meningococcal Vaccines, Combination Meningococcal Vaccines and
Meningococcal B Vaccines Markets - Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 33: Europe 15-Year Perspective for Meningococcal Vaccines
by Type - Percentage Breakdown of Value Sales for
Polysaccharide Meningococcal Vaccines, Conjugate Meningococcal
Vaccines, Combination Meningococcal Vaccines and Meningococcal
B Vaccines for the Years 2012, 2018 & 2027

FRANCE
Table 34: France Current & Future Analysis for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines - Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 35: France Historic Review for Meningococcal Vaccines by
Type - Polysaccharide Meningococcal Vaccines, Conjugate
Meningococcal Vaccines, Combination Meningococcal Vaccines and
Meningococcal B Vaccines Markets - Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 36: France 15-Year Perspective for Meningococcal Vaccines
by Type - Percentage Breakdown of Value Sales for
Polysaccharide Meningococcal Vaccines, Conjugate Meningococcal
Vaccines, Combination Meningococcal Vaccines and Meningococcal
B Vaccines for the Years 2012, 2018 & 2027

GERMANY
Table 37: Germany Current & Future Analysis for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines - Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 38: Germany Historic Review for Meningococcal Vaccines by
Type - Polysaccharide Meningococcal Vaccines, Conjugate
Meningococcal Vaccines, Combination Meningococcal Vaccines and
Meningococcal B Vaccines Markets - Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 39: Germany 15-Year Perspective for Meningococcal
Vaccines by Type - Percentage Breakdown of Value Sales for
Polysaccharide Meningococcal Vaccines, Conjugate Meningococcal
Vaccines, Combination Meningococcal Vaccines and Meningococcal
B Vaccines for the Years 2012, 2018 & 2027

ITALY
Table 40: Italy Current & Future Analysis for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines - Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 41: Italy Historic Review for Meningococcal Vaccines by
Type - Polysaccharide Meningococcal Vaccines, Conjugate
Meningococcal Vaccines, Combination Meningococcal Vaccines and
Meningococcal B Vaccines Markets - Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 42: Italy 15-Year Perspective for Meningococcal Vaccines
by Type - Percentage Breakdown of Value Sales for
Polysaccharide Meningococcal Vaccines, Conjugate Meningococcal
Vaccines, Combination Meningococcal Vaccines and Meningococcal
B Vaccines for the Years 2012, 2018 & 2027

UNITED KINGDOM
Table 43: UK Current & Future Analysis for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines - Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 44: UK Historic Review for Meningococcal Vaccines by Type -
Polysaccharide Meningococcal Vaccines, Conjugate
Meningococcal Vaccines, Combination Meningococcal Vaccines and
Meningococcal B Vaccines Markets - Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 45: UK 15-Year Perspective for Meningococcal Vaccines by
Type - Percentage Breakdown of Value Sales for Polysaccharide
Meningococcal Vaccines, Conjugate Meningococcal Vaccines,
Combination Meningococcal Vaccines and Meningococcal B Vaccines
for the Years 2012, 2018 & 2027

REST OF EUROPE
Table 46: Rest of Europe Current & Future Analysis for
Meningococcal Vaccines by Type - Polysaccharide Meningococcal
Vaccines, Conjugate Meningococcal Vaccines, Combination
Meningococcal Vaccines and Meningococcal B Vaccines -
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 47: Rest of Europe Historic Review for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines Markets - Independent
Analysis of Annual Sales in US$ Billion for Years 2012 through
2017

Table 48: Rest of Europe 15-Year Perspective for Meningococcal
Vaccines by Type - Percentage Breakdown of Value Sales for
Polysaccharide Meningococcal Vaccines, Conjugate Meningococcal
Vaccines, Combination Meningococcal Vaccines and Meningococcal
B Vaccines for the Years 2012, 2018 & 2027

ASIA-PACIFIC
Table 49: Asia-Pacific Current & Future Analysis for
Meningococcal Vaccines by Type - Polysaccharide Meningococcal
Vaccines, Conjugate Meningococcal Vaccines, Combination
Meningococcal Vaccines and Meningococcal B Vaccines -
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 50: Asia-Pacific Historic Review for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines Markets - Independent
Analysis of Annual Sales in US$ Billion for Years 2012 through
2017

Table 51: Asia-Pacific 15-Year Perspective for Meningococcal
Vaccines by Type - Percentage Breakdown of Value Sales for
Polysaccharide Meningococcal Vaccines, Conjugate Meningococcal
Vaccines, Combination Meningococcal Vaccines and Meningococcal
B Vaccines for the Years 2012, 2018 & 2027

REST OF WORLD
Table 52: Rest of World Current & Future Analysis for
Meningococcal Vaccines by Type - Polysaccharide Meningococcal
Vaccines, Conjugate Meningococcal Vaccines, Combination
Meningococcal Vaccines and Meningococcal B Vaccines -
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 53: Rest of World Historic Review for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines Markets - Independent
Analysis of Annual Sales in US$ Billion for Years 2012 through
2017

Table 54: Rest of World 15-Year Perspective for Meningococcal
Vaccines by Type - Percentage Breakdown of Value Sales for
Polysaccharide Meningococcal Vaccines, Conjugate Meningococcal
Vaccines, Combination Meningococcal Vaccines and Meningococcal
B Vaccines for the Years 2012, 2018 & 2027

IV. COMPETITION
Total Companies Profiled: 32
Read the full report: https://www.reportlinker.com/p05957343/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001